Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Katsunori Shinozaki"'
Autor:
Masashi Kanai, Takahisa Kawaguchi, Masahito Kotaka, Dai Manaka, Junichi Hasegawa, Akinori Takagane, Yoshinori Munemoto, Takeshi Kato, Tetsuya Eto, Tetsuo Touyama, Takanori Matsui, Katsunori Shinozaki, Shigemi Matsumoto, Tsunekazu Mizushima, Masaki Mori, Junichi Sakamoto, Atsushi Ohtsu, Takayuki Yoshino, Shigetoyo Saji, Fumihiko Matsuda
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 7808-7814 (2023)
Abstract Objective Dihydropyrimidine dehydrogenase (DPYD) genotype is closely associated with fluoropyrimidine (FP)‐induced toxicities in Caucasian population and European Medicines Agency now recommends DPYD genotype‐based FP dosing strategy. Pa
Externí odkaz:
https://doaj.org/article/22d0decfa3754b00b4a85b0440d3496a
Autor:
Hiroyuki Arai, Eisuke Inoue, Kensei Yamaguchi, Narikazu Boku, Hiroki Hara, Tomohiro Nishina, Masahiro Tsuda, Kohei Shitara, Katsunori Shinozaki, Shinichiro Nakamura, Ichinosuke Hyodo, Kei Muro, Mitsuru Sasako, Masanori Terashima, Takako E. Nakajima
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7673-7682 (2021)
Abstract Background In the JCOG1108/WJOG7312G trial, a combination (FLTAX) of 5‐fluorouracil (FU) /leucovorin (FL) and paclitaxel (PTX) did not show superiority in overall survival (OS) to FL in untreated patients with severe peritoneal metastasis
Externí odkaz:
https://doaj.org/article/5a49fbf951434c0199f4f695f82816eb
Autor:
Mashu Futagawa, Hideki Yamamoto, Mariko Kochi, Yusaku Urakawa, Reimi Sogawa, Fumino Kato, Mika Okazawa-Sakai, Daisuke Ennishi, Katsunori Shinozaki, Hirofumi Inoue, Hiroyuki Yanai, Akira Hirasawa
Publikováno v:
Hereditary Cancer in Clinical Practice, Vol 19, Iss 1, Pp 1-7 (2021)
Abstract Background RAD51D (RAD51 paralog D) is an intermediate cancer susceptibility gene for primary ovarian cancer, including fallopian tube and peritoneal carcinomas and breast cancer. Although gynecological non-epithelial tumors such as uterine
Externí odkaz:
https://doaj.org/article/44be1e99494e4db990fec38e106ce428
Autor:
Katsumaro Kubo, Koichi Wadasaki, Daisuke Komichi, Tamito Sasaki, Hiroyasu Yamada, Yasuhiro Matsugu, Toshiyuki Itamoto, Mihoko Doi, Katsunori Shinozaki
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0227305 (2019)
We aimed to demonstrate a single institution experience of treatment of pancreatic ductal carcinoma and to identify the role of radiation therapy. We assessed all patients who were diagnosed with pancreatic ductal carcinoma from January 2011 to Decem
Externí odkaz:
https://doaj.org/article/9c941c1cca5341638e5508c904a39d64
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 1, Pp 246-251 (2014)
A 50-year-old man was referred to our hospital because of a 2-month history of painful gingival swelling. Histopathological examination of the biopsy specimen showed a metastatic adenocarcinoma, and a chest-abdominopelvic CT showed multiple metastase
Externí odkaz:
https://doaj.org/article/bc5a4af43ad4436886a2ed2fdf11943b
Autor:
Takahiko Ito, Atsuo Takashima, Kentaro Yamazaki, Hiroki Yukami, Hiroyuki Uetake, Masahiro Tsuda, Takeshi Suto, Toshikazu Moriwaki, Naotoshi Sugimoto, Hitoshi Ojima, Yasumasa Takii, Hisateru Yasui, Taito Esaki, Akihito Tsuji, Masahiro Goto, Masayuki Saruta, Satoshi Otsu, Katsunori Shinozaki, Toshiyoshi Fujiwara, Takao Tamura, Eishi Baba, Manabu Shiozawa, Tadamichi Denda, Hideki Ueno, Kengo Nagashima, Yasuhiro Shimada
Publikováno v:
International Journal of Clinical Oncology. 27:1450-1458
Primary tumor location is considered a predictor of overall survival (OS) in RAS wild-type (WT) metastatic colorectal cancer (mCRC) treated with bevacizumab (BEV) or an anti-epidermal growth factor antibody (cetuximab or panitumumab [CET/PAN]) as fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc8a34b5e27b91bcfdbbe55f51e72c38
https://doi.org/10.1007/s10147-022-02208-7
https://doi.org/10.1007/s10147-022-02208-7
Autor:
Masashi Kanai, Takahisa Kawaguchi, Masahito Kotaka, Dai Manaka, Junichi Hasegawa, Akinori Takagane, Yoshinori Munemoto, Takeshi Kato, Tetsuya Eto, Tetsuo Touyama, Takanori Matsui, Katsunori Shinozaki, Shigemi Matsumoto, Tsunekazu Mizushima, Masaki Mori, Junichi Sakamoto, Atsushi Ohtsu, Takayuki Yoshino, Shigetoyo Saji, Fumihiko Matsuda
Publikováno v:
Cancer medicineREFERENCES.
Dihydropyrimidine dehydrogenase (DPYD) genotype is closely associated with fluoropyrimidine (FP)-induced toxicities in Caucasian population and European Medicines Agency now recommends DPYD genotype-based FP dosing strategy.The current study aimed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0cf8ec1b2fdb0b8ae2aa95e62b7ecdb
https://pubmed.ncbi.nlm.nih.gov/36524458
https://pubmed.ncbi.nlm.nih.gov/36524458
Autor:
Yasunori Emi, Yoshihiro Okita, Shohei Ueno, Eiji Oki, Katsunori Shinozaki, Hidenobu Matsushita, Masaru Fukahori, Yoshihiko Maehara, Futoshi Uno, Masaki Mori, Hiroshi Saeki, Eishi Baba, Tomomi Kashiwada, Mototsugu Shimokawa, Akitaka Makiyama, Hirofumi Kawanaka
Publikováno v:
International Journal of Clinical Oncology. 26:345-354
In a randomized pivotal global phase III study, S-1 and oxaliplatin 100 mg/m2 (SOX100) combination chemotherapy was as effective as S-1 and cisplatin for advanced gastric cancer (AGC) and showed a favorable safety profile. In this phase II study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::867d1d15818f07060484f981844da5f7
https://doi.org/10.1007/s10147-020-01803-w
https://doi.org/10.1007/s10147-020-01803-w
Autor:
Hiroshi Katayama, Narikazu Boku, Kensei Yamaguchi, Tomohiro Nishina, Takeshi Sakamoto, Hiroki Hara, Shinichiro Nakamura, Masanori Terashima, Kohei Shitara, Takako Eguchi Nakajima, Ichinosuke Hyodo, Kei Muro, Junki Mizusawa, Katsunori Shinozaki
Publikováno v:
Gastric Cancer. 23:677-688
Oral fluoropyrimidine plus cisplatin is often not tolerated by patients with severe peritoneal metastases of gastric cancer. Combination of 5-fluorouracil (5-FU), l-leucovorin (l-LV), and paclitaxel (FLTAX) has promising activity for such patients. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1d4e5e4710230d4ffddfd506b324bc8
https://doi.org/10.1007/s10120-020-01043-x
https://doi.org/10.1007/s10120-020-01043-x
Autor:
Katsunori Shinozaki, Ichinosuke Hyodo, Mitsuru Sasako, Masanori Terashima, Kensei Yamaguchi, Kei Muro, Tomohiro Nishina, Kohei Shitara, Masahiro Tsuda, Eisuke Inoue, Shinichiro Nakamura, Narikazu Boku, Takako E. Nakajima, Hiroki Hara, Hiroyuki Arai
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 21, Pp 7673-7682 (2021)
Cancer Medicine, Vol 10, Iss 21, Pp 7673-7682 (2021)
Background In the JCOG1108/WJOG7312G trial, a combination (FLTAX) of 5‐fluorouracil (FU) /leucovorin (FL) and paclitaxel (PTX) did not show superiority in overall survival (OS) to FL in untreated patients with severe peritoneal metastasis of gastri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::725a0159c230b9eec76a9771209fa01e
https://pubmed.ncbi.nlm.nih.gov/34655175
https://pubmed.ncbi.nlm.nih.gov/34655175